Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.

Medical oncology (Northwood, London, England) - 1 Mar 2017

Helbig Grzegorz, Wichary Ryszard, Torba Karolina, Kyrcz-Krzemień Sławomira

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Exons
Share to Janus Kinase 2
Share to Nitriles
Share to Polycythemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Pyrazoles

Share to Pyrimidines

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 28120162
DOI: 10.1007/s12032-017-0891-8
PMCID: PMC5263189

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene.PMID 28120162Read ↗

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Semantic proximity Read ↗

Ruxolitinib in a Child With JAK2 Exon 12 Mutant Polycythemia Vera.Semantic proximity Read ↗

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.Semantic proximity Read ↗

Polycythemia vera is not initiated by JAK2 mutationSemantic proximity Read ↗

JAK2 exon 12 mutation in JAK2V617F-negative polycythemia vera.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia veraSemantic proximity Read ↗

Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha.Semantic proximity Read ↗

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].Semantic proximity Read ↗

Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.Semantic proximity Read ↗

Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Semantic proximity Read ↗

Trans-splenic Sharp Recanalization, Extra-Anatomic Portal Vein Reconstruction, and Intrahepatic Portosystemic Shunt creation for the Treatment of Portal Hypertension in a Patient with Polycythemia Vera and JAK2 Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.